Healthcare hires of note
Here's a selection of recent executive hires across healthcare and life sciences.
Here's a selection of recent executive hires across healthcare and life sciences.
In the latest salvo in the ongoing legal skirmish between the two companies, Natera accused CareDx of infringing two patents covering Natera’s DNA testing technology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A jury ruled that Natera owes $44.9 million in damages to CareDx on grounds that Natera intentionally mislead the transplant community regarding its Prospera Kidney Transplant Technology by likening it to CareDx's AlloSure test; the jury also ruled that CareDx engaged in two accounts of false advertising.
Several fundamentals have changed to accelerate growth in the genomics space, spurring our second look into the sector.
Natera's lead product, its Panorama test, screens for fetal abnormalities, including Down syndrome, Edwards syndrome and Turner syndrome, as well as severe organ abnormalities and fetal viability.
Natera, a diagnostics company most known for its prenatal testing segment, just raised $55.5 million to expand its salesforce and marketing reach, and invest in R&D that pivots toward the field of precision medicine. The dollars will go toward expanding its global sales and marketing force, as well as expanding its R&D for existing tests and […]
For years, pregnant women have had a choice of undergoing traditional blood tests or more invasive and potentially dangerous procedures to rule out the chance of any chromosomal abnormalities such as Down Syndrome that may afflict their unborn child. The problem is that while the prenatal blood tests are safe and unlike the more invasive […]